表紙
市場調查報告書

癌症幹細胞治療藥的全球市場:2019年∼2023年

Global Cancer Stem Cell Therapeutics Market 2019-2023

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 865028
出版日期 內容資訊 英文 104 Pages
訂單完成後即時交付
價格
Back to Top
癌症幹細胞治療藥的全球市場:2019年∼2023年 Global Cancer Stem Cell Therapeutics Market 2019-2023
出版日期: 2019年05月29日內容資訊: 英文 104 Pages
簡介

癌症是全世界最常見的死因之一。乳癌、膀胱癌、肺癌、白血病、胰臟癌、前列腺癌等,由於各種癌症的罹患率高,全世界死亡率上升。在匈牙利、荷蘭、丹麥、克羅埃西亞等國,過去數年癌症的病例增加。預計在全世界由於癌症相關罹患率持續增加,促進癌症幹細胞治療藥的需求。預計全球癌症幹細胞治療藥市場在預測期間內以11%以上的年複合成長率成長。

本報告提供全球癌症幹細胞治療藥市場相關調查分析,市場規模與成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 報告的範圍

  • 簡介1
  • 簡介2
  • 美金的貨幣換算比率

第3章 市場情形

  • 市場生態系統
  • 市場特徵
  • 市場區隔分析

第4章 市場規模

  • 市場定義
  • 市場規模(2018年)
  • 市場規模及預測(2018年∼2023年)

第5章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情況

第6章 市場區隔:各類型

  • 市場區隔:各類型
  • 各類型比較:市場規模及預測(2018年∼2023年)
  • 同類幹細胞移植
  • 自體幹細胞移植
  • 市場機會:各類型

第7章 客戶形勢

第8章 地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模及預測(2018年∼2023年)
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 市場機會

第9章 決策架構

第10章 成長要素與課題

  • 市場成長要素
  • 市場課題

第11章 市場趨勢

  • 癌症幹細胞重要的信號傳達途徑相關研究活動的增加
  • 癌症幹細胞的鑑定中幹細胞標記的效用
  • 使用了誘導性多功能幹細胞(iPS細胞)的First-in-Class治療藥的開發

第12章 業者情勢

  • 概要
  • 創造性破壞狀況

第13章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • Cellerant Therapeutics, Inc.
  • Celularity Inc.
  • Gamida Cell Ltd.
  • Nohla Therapeutics, Inc.
  • 大日本住友製藥

第14章 附錄

  • 調查方法
  • 簡稱的清單
  • 供應商的市場定位定義

第15章 關於TECHNAVIO

目錄
Product Code: IRTNTR31416

About this market

Cancer is one of the most common causes of deaths across the world. The high prevalence of various types of cancer, such as breast cancer, bladder cancer, lung cancer, leukemia, pancreatic cancer, and prostate cancer, has increased the mortality rate across the world. Countries such as Hungary, Netherlands, Denmark, and Croatia have witnessed an increase in the number of cancer cases over the past few years. The growing instances of cancer-related morbidity across the world will fuel the demand for cancer stem cell therapeutics and drive the growth of the global cancer stem cell therapy market size at a CAGR of over 11% during the forecast period.

Market Overview

Strong drug pipeline

The prevalence of cancer across the world is driving many vendors in the market to develop novel stem cell therapies. Several drugs are in the late stages of clinical trials and are expected to receive marketing approvals over the forecast period. For instance, CanStem 303C is an orally administered drug developed to inhibit cancer cell pathways in patients with metastatic pancreatic ductal adenocarcinoma. The drug is currently in Phase III of clinical trials and is expected to be launched in the US by 2021.

Side-effects of stem cell transplant

Stem cell transplant causes several immediate side effects such as fatigue, vomiting, low levels of platelets and red blood cells, and diarrhea. It may also cause several long term effects such as infertility, eye disorders, early menopause, lung and bone damage, and risk of developing other cancer types. These risk factors may hinder the growth of the global cancer stem cell therapy market size.

For the detailed list of factors that will drive and challenge the growth of the cancer stem cell therapy market size during 2019-2023.

Competitive Landscape

The market appears to be fairly concentrated with few players occupying the market share. Companies such as Cellerant Therapeutics Inc. and Celularity Inc. have intensified competition. Factors such as the rising prevalence of cancer and the strong drug pipeline will provide significant growth opportunities for cancer stem cell therapy companies. Cellerant Therapeutics Inc., Celularity Inc., Gamida Cell Ltd., Nohla Therapeutics Inc., and Sumitomo Dainippon Pharma Co. Ltd. are some of the major companies covered in this report.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY TYPE

  • Market segmentation by type
  • Comparison by type
  • Allogeneic stem cell transplant - Market size and forecast 2018-2023
  • Autologous stem cell transplant - Market size and forecast 2018-2023
  • Market opportunity by type

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023

Key leading countries

  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Increasing research activity on cancer stem cell key signaling pathways
  • Availability of stem cell markers in the identification of cancer stem cells
  • Development of first-in-class therapeutics using induced pluripotent stem cells

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Cellerant Therapeutics, Inc.
  • Celularity Inc.
  • Gamida Cell Ltd.
  • Nohla Therapeutics, Inc.
  • Sumitomo Dainippon Pharma Co. Ltd.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Global oncology therapeutics market
  • Exhibit 02: Segments of global oncology therapeutics market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2018
  • Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 09: Five forces analysis 2018
  • Exhibit 10: Five forces analysis 2023
  • Exhibit 11: Bargaining power of buyers
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Threat of new entrants
  • Exhibit 14: Threat of substitutes
  • Exhibit 15: Threat of rivalry
  • Exhibit 16: Market condition - Five forces 2018
  • Exhibit 17: Type - Market share 2018-2023 (%)
  • Exhibit 18: Comparison by type
  • Exhibit 19: Allogeneic stem cell transplant - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 20: Allogeneic stem cell transplant - Year-over-year growth 2019-2023 (%)
  • Exhibit 21: Allogeneic stem cell transplants under development
  • Exhibit 22: Autologous stem cell transplant - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Autologous stem cell transplant - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Market opportunity by type
  • Exhibit 25: Customer landscape
  • Exhibit 26: Market share by geography 2018-2023 (%)
  • Exhibit 27: Geographic comparison
  • Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 30: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 31: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 32: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 33: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 34: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: Key leading countries
  • Exhibit 37: Market opportunity
  • Exhibit 38: Late-stage cancer stem cell therapy
  • Exhibit 39: Impact of drivers and challenges
  • Exhibit 40: Vendor landscape
  • Exhibit 41: Landscape disruption
  • Exhibit 42: Vendors covered
  • Exhibit 43: Vendor classification
  • Exhibit 44: Market positioning of vendors
  • Exhibit 45: Cellerant Therapeutics Inc. - Vendor overview
  • Exhibit 46: Cellerant Therapeutics Inc. - Key offerings
  • Exhibit 47: Celularity Inc. - Vendor overview
  • Exhibit 48: Celularity Inc. - Key offerings
  • Exhibit 49: Gamida Cell Ltd. - Vendor overview
  • Exhibit 50: Gamida Cell Ltd. - Business segments
  • Exhibit 51: Gamida Cell Ltd. - Key offerings
  • Exhibit 52: Nohla Therapeutics Inc. - Vendor overview
  • Exhibit 53: Nohla Therapeutics Inc. - Key offerings
  • Exhibit 54: Sumitomo Dainippon Pharma Co. Ltd. - Vendor overview
  • Exhibit 55: Sumitomo Dainippon Pharma Co. Ltd. - Business segments
  • Exhibit 56: Sumitomo Dainippon Pharma Co. Ltd. - Organizational developments
  • Exhibit 57: Sumitomo Dainippon Pharma Co. Ltd. - Segment focus
  • Exhibit 58: Sumitomo Dainippon Pharma Co. Ltd. - Key offerings
  • Exhibit 59: Validation techniques employed for market sizing
  • Exhibit 60: Definition of market positioning of vendors
Back to Top